BAN2401 Phase 3 Clinical Trial Starting April 2019

We are enthusiastic about the results of the BAN2401 phase 2 clinical trial for dementia. The study assessed changes from baseline to 18 months in biomarkers measuring the underlying disease pathophysiology, including changes in amyloid accumulated in the brain as measured by amyloid PET (positron emission tomography). The clinical endpoints of Alzheimer’s Disease Composite Score …

BAN2401 Phase 3 Clinical Trial Starting April 2019 Read More »